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EDITORIAL COMMENT
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of Periodic Breathing
Implications for
Mortality in Heart Failure*
T. Douglas Bradley, MD
Toronto, Canada
Periodic breathing is a regularly recurring waxing and
waning of tidal volume due to oscillations in central respi-
ratory drive. It is a sign of respiratory control system
instability. Under normal conditions, the respiratory and
circulatory systems work in concert to deliver O2 according
to metabolic demands, and to excrete CO2 to maintain
acid-base homeostasis. As a result, arterial PO2 (PaO2),
PCO2 (PaCO2) and pH are held within narrow limits. To
accomplish this precise matching of ventilation with meta-
bolic demands, respiration is regulated by a rapidly respon-
sive negative feedback system consisting of a central con-
troller and a peripheral plant. The central controller is
comprised of the peripheral and central chemoreceptors,
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which detect alterations in PaO2, PaCO2, and pH, and the
brainstem respiratory motor neurons, which generate a
central respiratory drive proportional to the degree of
chemoreceptor stimulation. The plant, consisting of the
respiratory muscles, rib cage, and lungs, alters ventilation in
response to changes in central respiratory drive. These
alterations in ventilation in turn provoke changes in arterial
blood gas tensions (1,2).
Several factors stabilize this respiratory control system.
First, alterations in arterial blood gas tensions in the lung are
fed back rapidly to the chemoreceptors, owing to a short
lung to chemoreceptor circulation time (2). This damps
fluctuations in ventilation, just as a rapidly responsive
thermostat will damp fluctuations in room temperature.
Second, normal chemoreceptor gain is just sufficient to
rapidly correct deviations in PaCO2 and PaO2 from their set
points, but not to overcorrect. Together, these two factors
prevent overshooting of ventilation in response to small
increases in chemostimulation. Third, normally the set
point for a ventilatory response to CO2 is well above the
apneic threshold (1,3). Because PaCO2 is normally the
primary stimulus to breathe, maintaining PaCO2 well above
this threshold facilitates stability of ventilation and arterial
blood gas tensions.
In general, periodic breathing is a manifestation of
underdamping of the respiratory control system with recur-
rent over- and undershooting of ventilation. Factors that
predispose to respiratory control system instability include
prolonged lung to chemoreceptor circulatory delay, in-
creased chemoreceptor gain and arousals from sleep that
trigger hyperventilation, and a low PaCO2 close to the
apneic threshold. The critical factor causing very low fre-
quency fluctuations in ventilation in most forms of periodic
breathing is an increased amplitude of oscillations in PaCO2
(1). The wider the fluctuations in PaCO2, the greater the
amplitude of ventilatory oscillations. In extreme cases,
ventilatory overshoot causes PaCO2 to fall below the apneic
threshold, resulting in central apnea. When PaCO2 falls but
remains above this threshold, a minimal level of ventilation
(i.e., hypopnea) is maintained. The observation that peri-
odic breathing during wakefulness at high altitude and
during sleep in patients with congestive heart failure (CHF)
can be reversed by inhalation of a low concentration of CO2
emphasizes the critical role of hypocapnia and fluctuations
in PaCO2 in its pathogenesis (4,5).
Patients with CHF are prone to developing instability of
their respiratory control systems and, therefore, periodic
breathing. Because of low cardiac output, lung to chemo-
receptor circulation time is increased, slowing the response
time of the negative feedback loop that modulates ventila-
tion. In addition, a substantial proportion of patients with
CHF hyperventilate and have chronic hypocapnia. This
tendency to hyperventilate is associated with increased
peripheral and central chemosensitivity, and with elevated
left ventricular filling pressures (6,7). The latter may give
rise to pulmonary congestion that can stimulate pulmonary
vagal irritant receptors. Stimulation of these receptors aug-
ments central respiratory drive and provokes hyperventila-
tion. The resultant hypocapnia combined with a tendency to
metabolic alkalosis secondary to diuretics will tend to keep
PaCO2 close to the apneic threshold (3,8,9). In this setting,
even small increases in ventilation can drive PaCO2 below
this threshold level.
Periodic breathing occurs most commonly when respira-
tion is under predominantly metabolic control, such as
during non-rapid eye movement sleep (non-REM) (1).
Conversely, it occurs less commonly when non-metabolic,
behavioral elements exert a significant influence on respira-
tory control, such as during wakefulness and rapid eye
movement (REM) sleep. These non-metabolic influences
include phonation, coughing, swallowing, and dreaming. In
patients with CHF, periodic breathing occurs most com-
monly during non-REM sleep, where it is known as
Cheyne-Stokes respiration with central sleep apnea (1). The
main clinical significance of this condition is that it is
associated with increased mortality independent of other
risk factors (10). The reason for this is not clear, but it may
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be attributable to recurrent apneas accompanied by inter-
mittent hypoxia, arousals from sleep, and sympathetic ner-
vous system activation causing surges in blood pressure and
heart rate (11,12). Cheyne-Stokes respiration occasionally
occurs during wakefulness, at which time it also seems to be
associated with increased risk of mortality (13). In this issue
of the Journal, Leite et al. (14) extend those findings by
demonstrating that exercise-related periodic breathing
(EPB) in patients with CHF is also associated with in-
creased risk of death independent of other risk factors.
The observation that periodic breathing would occur
during exercise is rather counterintuitive, because exercise is
performed during wakefulness when non-metabolic behav-
ioral influences should be at play. However, during exercise,
the increased metabolic requirements for O2 consumption
and CO2 production mandate that respiration falls predom-
inantly under the influence of the chemical-metabolic re-
spiratory control system. Although this was not the main
focus of the study, the data from the Leite et al. (14) study
provide some clues as to the pathophysiology of EPB in
their subjects. First, as with Cheyne-Stokes respiration
during sleep, subjects with EPB had lower PCO2 at rest
than did subjects without EPB. Second, the higher slope of
the relationship between change in minute ventilation (VE)
and change in CO2 production (VCO2) in subjects with
EPB suggests that they had greater chemosensitivity to CO2
than did subjects without EPB. Because it has been dem-
onstrated that PaCO2 is inversely proportional to left
ventricular filling pressure, it is likely that pulmonary venous
pressure was higher in subjects with than in those without
EPB (8). If so, then one of the probable causes of the
relative hyperventilation in the EPB group was a further rise
in pulmonary venous pressure at the onset of exercise.
Third, subjects had a markedly prolonged EPB cycle length,
averaging 79 s. This compares with a much shorter cycle
length of periodic breathing during central sleep apnea in
patients without CHF of approximately 37 s (15), suggest-
ing prolonged lung to chemoreceptor circulatory delay.
However, because circulation time was not measured in
either those with or those without EPB, there was no direct
evidence of greater circulation time in the former. Although
they did not measure PaO2 during exercise, hypoxia is
unlikely to have played a role in causing hypocapnia because
patients with stable CHF are generally normoxic and are
unlikely to become hypoxic during exercise (12). In addi-
tion, arousals from sleep obviously did not contribute to
hyperventilation. Unfortunately, because breathing pattern
during rest was not described, one cannot be sure that
periodic breathing was not already present before the onset
of exercise.
It is interesting to note that the prevalence of EPB in
study subjects was 30%, which is very similar to the
prevalence of Cheyne-Stokes respiration with central sleep
apnea reported in patients with CHF (16). Although the
authors did not perform sleep studies in their subjects, it
would have been interesting to see whether the presence of
EPB is associated with the Cheyne-Stokes respiration
during sleep.
The most important finding of Leite et al. was that the
presence of EPB was associated with a 2.97 higher relative
risk of death than in subjects without EPB, after controlling
for the presence of other risk factors. These findings are
similar to those reported by Corra et al. (17), but there are
important differences that raise questions about the gener-
alizability of the results. Leite et al. (14) found a 30%
prevalence of EPB among 84 patients, whereas Corra et al.
(17) found a prevalence of only 12% in 323 patients. This
difference might be accounted for by the more liberal
definition of “EPB” as three consecutive cycles of oscillatory
ventilation used by Leite et al. (14). In contrast, Corra et al.
(17) defined EPB as oscillatory ventilation occupying at
least 60% of the exercise time. The etiology of CHF also
differed. Leite et al. (14) included 11 (13%) subjects with
Chagas’ disease, a disorder particular to South America,
whereas Corra et al. (17) did not include such subjects. In
addition, the subjects of Leite et al. (14) were all undergoing
heart transplantation evaluation and were young, with a
mean age of 45 years. On the other hand, the subjects of
Corra et al. (17) were attending a general CHF clinic and
were older (mean age of 59 years). The most important
difference, however, was the very high death rate reported by
Leite et al. (14). Over a median follow-up period of 11
months, 31% of subjects died. The cumulative survival rate
at two years was only 57%, a rate much lower than that
reported in recent randomized trials of CHF therapy. In
contrast, Corra et al. (17) reported a much higher two-year
survival rate of 86%, which is probably more representative
of the general CHF population in the developed world.
Another factor that bears mentioning is the very low
proportion of subjects in Leite et al. (14) who are receiving
beta-adrenergic blocking agents (6%), which might account
for some of their excess mortality. This compares with
approximately 35% in Corra et al. (17). In both these
studies, subjects with EPB had a tendency to have worse
cardiac function, exercise capacity, and functional class than
those without EPB. Nevertheless, the similarities between
these two studies outweigh their differences: in both cases,
multivariate analyses designed to control for confounding
variables demonstrated an increased independent risk of
death associated with the presence of EPB.
Despite this multivariate analysis, the data of Leite et al.
(14) still leave unanswered the question of whether EPB
itself contributes to high mortality rates in CHF, rather
than simply being a sign of worse underlying cardiovascular
function. For example, sedentary patients with CHF will
not be exposed to EPB very often. If, on the other hand,
EPB is also associated with central sleep apnea, then excess
risk may be attributed to periodic breathing in general,
rather than specifically to EPB. Furthermore, as in the case
of Cheyne-Stokes respiration during sleep (7), it seems very
likely that left ventricular filling pressures were higher in
subjects with than in those without EPB. Elevated filling
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pressures are known to be associated with higher mortality
in CHF (18). However, filling pressures were not measured.
Notwithstanding such considerations, the data of Leite et al.
(14) add to the mounting evidence that instability of the
respiratory control system, whether manifest in periodic
breathing during sleep (10), resting wakefulness (13), or
exercise, heralds a poor prognosis in patients with CHF.
From the practical standpoint, these breathing disorders
can be easily and inexpensively identified by non-invasive
means and may add prognostic information over and above
that obtained from other cardiovascular assessments. More-
over, a small randomized trial suggested that treatment of
central sleep apnea by continuous positive airway pressure
can improve survival in patients with CHF (19). If these
results can be replicated in a larger trial, then periodic
breathing may become a therapeutic target in CHF. Ap-
proaches to specific therapy of EPB, however, have yet to
emerge. Nonetheless, to the credit of Leite et al. (14), their
work leads to the conclusion that, in the search for better
therapies for CHF, the pathophysiologic, prognostic, and
therapeutic implications of periodic breathing warrants
more intensive investigation.
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